A5033186004- Endometrial and Cervical Cancer Treatments
- Ovarian cancer diagnosis and treatment
- Cervical Cancer and HPV Research
- BRCA gene mutations in cancer
- Breast Cancer Treatment Studies
- Multiple and Secondary Primary Cancers
- Breast Lesions and Carcinomas
- Endometriosis Research and Treatment
- Cancer Immunotherapy and Biomarkers
- Brain Metastases and Treatment
- Cancer Diagnosis and Treatment
- PARP inhibition in cancer therapy
- Lung Cancer Treatments and Mutations
- Cancer and Skin Lesions
- Uterine Myomas and Treatments
- Genetic factors in colorectal cancer
- Management of metastatic bone disease
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Metastasis and carcinoma case studies
- Inflammatory Biomarkers in Disease Prognosis
- Reproductive System and Pregnancy
- Melanoma and MAPK Pathways
- Renal cell carcinoma treatment
- Colorectal and Anal Carcinomas
National Institute of Oncology
2024-2025
The Maria Sklodowska-Curie National Research Institute of Oncology
2015-2025
Centrum Onkologii
2007-2024
Centre Hospitalier Universitaire de Montpellier
2021
Hospital de São João
2020
Lublin Oncology Center
2019
Polskie Towarzystwo Gastroenterologii
2015
Krakow Cardiovascular Research Institute
2012
International Hereditary Cancer Center
2011
Jagiellonian University
2008
To estimate the risk of breast cancer in a woman who has CHEK2 mutation depending on her family history cancer.Seven thousand four hundred ninety-four BRCA1 mutation-negative patients with and 4,346 control women were genotyped for founder mutations (del5395, IVS2+1G>A, 1100delC, I157T).A truncating (IVS2+1G>A, or del5395) was present 227 (3.0%) 37 female controls (0.8%; odds ratio [OR], 3.6; 95% CI, 2.6 to 5.1). The OR higher first- second-degree relative (OR, 5.0; 3.3 7.6) than no 3.3; 2.3...
Abstract Introduction The purpose of this investigation was to evaluate the efficacy cisplatin chemotherapy in BRCA1 mutation carriers with metastatic breast cancer. Methods In a phase II, open-label study, 20 patients cancer who carried were treated 75 mg/m 2 intravenously every 3 weeks as part 21-day cycle for 6 cycles. Restaging studies assess response performed after cycles and 6, three months thereafter. Results Between July 2007 January 2009, enrolled. Baseline characteristics follows:...
Objective:The goal of the study was to compare conventional mammography (MG) and contrast-enhanced spectral (CESM) in preoperative women. Materials Methods:The approved by local Ethics Committee all participants provided informed consent.The included 152 consecutive patients with 173 breast lesions diagnosed on MG or CESM.All examinations consults were conducted one oncology centre.Non-ionic contrast agent, at a total dose 1.5 mL/kg body weight, injected intravenous.Subsequently, CESM exams...
BackgroundSENTIX (ENGOT-CX2/CEEGOG-CX1) is an international, multicentre, prospective observational trial evaluating sentinel lymph node (SLN) biopsy without pelvic dissection in patients with early-stage cervical cancer. We report the final preplanned analysis of secondary end-points: SLN mapping and outcomes intraoperative pathology.MethodsForty-seven sites (18 countries) experience participated SENTIX. preregistered stage IA1/lymphovascular space invasion-positive to IB2 (4 cm or smaller...
Background/Objectives: Sentinel lymph node biopsy (SLNB) is a minimally invasive technique used to assess lymphatic involvement in endometrial cancer (EC), offering reduced surgical morbidity compared routine lymphadenectomy. Despite its widespread use, the optimal combination of tracers for SLN detection remains subject debate. Methods: This retrospective cohort study included 119 patients with early-stage EC treated at Maria Skłodowska-Curie National Research Institute Oncology between...
Background Second-line treatment options for persistent, recurrent or metastatic (r/m) cervical cancer are limited. We investigated the safety, efficacy, and immunogenicity of therapeutic DNA-based vaccine VB10.16 combined with immune checkpoint inhibitor atezolizumab in patients human papillomavirus (HPV)16-positive r/m cancer. Patients methods This multicenter, single-arm, phase 2a study ( NCT04405349 , registered 26 May 2020) enrolled adult HPV16-positive received 3 mg (every weeks (Q3W)...
Background: Endometrial cancer (EC) incidence and mortality have been steadily rising globally over recent decades. The introduction of advanced molecular technologies, such as next-generation sequencing (NGS) alongside the FIGO 2023 classification, presents opportunities for refined diagnostics risk stratification. This study aimed to analyze differences in EC classification among oncology centers southeastern Poland. Methods: Data were collected from 461 consecutive patients newly...
Surgery remains the mainstay of treatment in patients with malignant phyllodes tumor breast (MPTB); however, extent surgery (breast conserving [BCS] versus mastectomy) and role adjuvant radiotherapy have been controversial. We report a single institution's experience MPTB. discuss controversial therapeutic aspects this rare tumor. Seventy MPTB treated primarily were evaluated. The mean age was 50 years (21–76), size 6 cm. Thirty-four (48.6%) total mastectomy, 36 (51.4%) BCS (lumpectomy or...
Here, the treatment methods and results of patients with phyllodes tumor breast (PT) distant metastases at a single institution are presented.A retrospective analysis was performed on group 295 PT treated from 1952 to 2010.Distant developed in 37 (12.5 %) patients; 3/160 (1.9 had benign PT, 6/36 (16.7 were considered borderline, 28/99 (28.3 malignant PT. Most frequently, located lungs; 28 (75.7 %), bone 7 (18.9 brain 4 (10.8 liver 2 (5.4 %). Metastases occurred overage 21 months (2-57) after...
<h3>Objective</h3> This study aimed to analyze the prognostic factors for overall and progression-free survival in patients with vulvar cancer. <h3>Methods</h3> international, multicenter, retrospective included 2453 diagnosed cancer at 100 different institutions. Inclusion criteria were institutional review board approval from each collaborating center, pathologic diagnosis of invasive carcinoma vulva, primary treatment performed participating center. Patients intraepithelial neoplasia or...
Mucinous breast carcinoma (MBC) represents approximately 1–6% of all malignant and is divided into pure (PMBC) mixed (MMBC) subtypes. This study presents the comparison clinical characteristics treatment results in 70 patients with PMBC 40 MMBC, treated at a single institution during 25 years. Performed analyses showed that only nodal status was different both Patients MMBC significantly higher incidence axillary metastases to (25% versus 10%, respectively). Instead, 10-year disease-free...
Mutations in the BRCA1, BRCA2 and PALB2 genes are well-established risk factors for development of breast and/or ovarian cancer. The frequency spectrum mutations these has not yet been examined population Southern Poland.We entire coding sequences BRCA1 genotyped a recurrent mutation gene (c.509_510delGA) 121 women with familial early-onset or cancer from Poland.A was identified 11 patients (9.1 %) 10 (8.3 %). Two founder accounted 91 % all carriers (c.5266dupC six c.181 T > G four...
To evaluate the addition of ofranergene obadenovec (ofra-vec, VB-111), a novel gene-based anticancer targeted therapy, to once week paclitaxel in patients with recurrent platinum-resistant ovarian cancer (PROC).
<ns3:p><b>Objective:</b> Scintigraphy with technetium-99m (Tc-99m) is essential for sentinel lymph node (SLN) detection in gynecological cancers, aiding preoperative planning and reducing unnecessary lymphadenectomy. However, traditional image interpretation subjective. This study applies numerical tools: signal-to-noise ratio (SNR) C factor (SLN SNR/ background SNR) to objectively assess scintigraphic quality protocol efficacy. <br><b>Materials methods:</b> A...
Nivolumab plus ipilimumab (NIVO+IPI) is a first-line treatment for metastatic renal cell carcinoma (mRCC) in intermediate- and poor-risk patients. Real-world evidence (RWE) studies are needed to validate its efficacy safety clinical practice. This multicenter retrospective study included 145 mRCC patients treated with NIVO+IPI at nine oncology centers Poland between May 2022 December 2024. Data on overall survival (OS), progression-free (PFS), objective response rate (ORR), disease control...
Abstract Background Immune checkpoint inhibitors (ICIs) have been employed in the adjuvant and metastatic setting of renal cell carcinoma (RCC) treatment. Among ICIs, combined immunotherapy has highest risk for immune-related adverse events (irAEs). We aimed to document incidence irAEs RCC patients treated with nivolumab ipilimumab as data from European population remain limited. Materials methods analysed 88 + between May 2022 June 2024 across six high-volume oncology units Poland. reviewed...
Immune checkpoint inhibitors have improved the treatment of metastatic renal cell carcinoma (RCC), with combination nivolumab (NIVO) and ipilimumab (IPI) showing promising results. However, not all patients benefit from these therapies, emphasizing need for reliable, easily assessable biomarkers. This multicenter study involved 116 advanced RCC treated NIVO + IPI across nine oncology centers in Poland. Blood markers such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte (PLR),...
<title>Abstract</title> <bold>Introduction: </bold>Endometrial cancer (EC) exhibits molecular heterogeneity, classified into four subtypes: POLEmut (POLE ultramutated), MMRd (mismatch repair deficient), p53abn (p53 abnormal), and NSMP (no specific profile). Tumors with multiple classifiers (multiple-classifier ECs) challenge risk stratification, particularly MMRd-p53abn POLEmut-related subtypes. <bold>Method: </bold>This study aims to assess the prevalence clinicopathological features of...